MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.890
+0.020
+0.52%
Opening 11:24 09/23 EDT
OPEN
3.870
PREV CLOSE
3.870
HIGH
3.910
LOW
3.870
VOLUME
13.92K
TURNOVER
--
52 WEEK HIGH
10.81
52 WEEK LOW
3.330
MARKET CAP
190.49M
P/E (TTM)
-16.1344
1D
5D
1M
3M
1Y
5Y
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will ...
GlobeNewswire · 09/03 03:00
BRIEF-Medicinova Announces Mn-001 Abstract Regarding Lipid Metabolism In Nash/Nafld Accepted For Presentation At The Liver Meeting 2021
reuters.com · 09/01 11:35
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled ...
GlobeNewswire · 09/01 10:30
BRIEF-Medicinova Announces Mn-166 (Ibudilast) Als Abstract Accepted For Presentation At The 32Nd International Symposium On Als/Mnd
reuters.com · 08/30 11:35
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regar...
GlobeNewswire · 08/30 10:30
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 61% if they invested three years ago
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...
Simply Wall St. · 08/16 15:23
MNOV: Animal Trials Commence Testing MN-166 as an MCM…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Preclinical Studies for BARDA Contract Underway In June 2021, MediciNova, Inc. (NASDAQ:MNOV) announced it initiated a sheep study and also reached an agreement to conduct a ...
Zacks Small Cap Research · 08/16 15:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNOV. Analyze the recent business situations of MediciNova Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNOV stock price target is 16.50 with a high estimate of 27.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 9.94M
% Owned: 20.29%
Shares Outstanding: 48.97M
TypeInstitutionsShares
Increased
13
372.14K
New
18
1.73M
Decreased
19
4.22M
Sold Out
21
765.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.85%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Himawan
President/Chief Executive Officer/Director
Yuichi Iwaki
Chief Financial Officer
Douglas Paulin
Vice President/IR Contact Officer
Geoffrey O'brien
Other/Director
Kazuko Matsuda
Independent Director
Carolyn Beaver
Independent Director
Hideki Nagao
No Data
  • All
  • Financials
  • Insiders
More
About MNOV
Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.